Dimensional Fund Advisors LP Has $7.39 Million Stake in Electromed, Inc. (NYSE:ELMD)

Dimensional Fund Advisors LP lowered its stake in shares of Electromed, Inc. (NYSE:ELMD) by 10.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 250,219 shares of the company’s stock after selling 28,243 shares during the quarter. Dimensional Fund Advisors LP owned about 2.96% of Electromed worth $7,394,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Russell Investments Group Ltd. acquired a new stake in shares of Electromed during the 4th quarter worth approximately $37,000. IFP Advisors Inc bought a new stake in shares of Electromed during the 4th quarter worth $59,000. Quantbot Technologies LP acquired a new stake in Electromed in the fourth quarter valued at about $99,000. Bailard Inc. acquired a new stake in Electromed in the fourth quarter valued at about $224,000. Finally, Jump Financial LLC bought a new position in Electromed in the fourth quarter valued at about $237,000. Institutional investors own 40.82% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on ELMD. B. Riley initiated coverage on shares of Electromed in a report on Thursday, February 20th. They issued a “buy” rating and a $38.00 target price for the company. StockNews.com cut shares of Electromed from a “strong-buy” rating to a “buy” rating in a research note on Thursday.

Insider Activity at Electromed

In other Electromed news, Director Andrew Summers sold 50,751 shares of the business’s stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $27.30, for a total value of $1,385,502.30. Following the transaction, the director now directly owns 65,714 shares of the company’s stock, valued at approximately $1,793,992.20. The trade was a 43.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Kathleen Skarvan sold 38,954 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $29.28, for a total transaction of $1,140,573.12. Following the transaction, the director now owns 32,622 shares in the company, valued at $955,172.16. The trade was a 54.42% decrease in their position. The disclosure for this sale can be found here. Insiders sold 133,618 shares of company stock worth $3,821,636 over the last three months. Company insiders own 14.00% of the company’s stock.

Electromed Price Performance

ELMD opened at $22.20 on Monday. The company’s 50 day moving average price is $23.51 and its two-hundred day moving average price is $27.38. The firm has a market capitalization of $189.97 million, a price-to-earnings ratio of 29.60 and a beta of 0.46. Electromed, Inc. has a fifty-two week low of $13.74 and a fifty-two week high of $35.56.

Electromed declared that its Board of Directors has initiated a stock repurchase program on Monday, March 10th that permits the company to repurchase $5.00 million in outstanding shares. This repurchase authorization permits the company to buy up to 2.4% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s board believes its shares are undervalued.

About Electromed

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions.